Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
REVENUES
COST AND EXPENSES
Research and Development	2,237	5,825
General and Administrative	158,444	187,185
Consulting and Professional Fees	82,529	70,494
Rent	11,871	0
Total Costs and Expenses	255,081	263,504
OPERATING LOSS	(255,081)	(263,504)
OTHER INCOME & (EXPENSES)
Interest Expense	(14,571)	(8,884)
Loss on Settlement of Debt through Equity Issuance	(587,500)	648,500
Interest Income	260	0
Total Other Income & (Expense)	(601,811)	(657,384)
NET INCOME (LOSS) before loss attributable to noncontrolling interest in Entest Biomedical, Inc. and equity in subsidiary losses	(856,892)	(920,888)
(Net Income) Loss attributable to noncontrolling interest in Entest Biomedical, Inc.	0	0
NET INCOME (LOSS) before equity in subsidiary losses	(856,892)	(920,888)
Equity in Net Income (Loss) of Entest Biomedical, Inc.	0	0
NET INCOME (LOSS)	(856,892)	(920,888)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	94,603	6,801
NET INCOME (LOSS) available to common shareholders	$ (762,289)	$ (914,087)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0002)	$ (0.0004)
Weighted average number of shares outstanding	3,432,648,195	2,603,403,841